Skip to content
CNS Clinical Research

Houston, Texas

CNS clinical trials in Houston, TX

127 CNS studies are recruiting participants at sites in Houston as of November 16, 2026, according to ClinicalTrials.gov. CNS Clinical Research can help you understand your options and connect with a study team.

Call (888) 520-7418
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Houston at a glance

  • 127 studies are recruiting at a site in Houston.
  • By phase: Phase 1 (5), Phase 1/2 (5), Phase 2 (16), Phase 2/3 (1), Phase 3 (41), Phase 4 (3), No phase (40), Observational (16). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (70), university, hospital or other (54), government (3).
  • By research area: Depression (43), Parkinson's Disease (22), Epilepsy (21), Schizophrenia (16), Multiple Sclerosis (10), Migraine (8), Bipolar Disorder (5), ADHD (2).
  • Most recent update to one of these records: November 16, 2026.

Depression studies recruiting in Houston

Basic details from each study's public record (the 30 most recently updated of 127). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder

    • Phase 2
    • Ages 18 to 70
    • All sexes
    Sponsor
    Supernus Pharmaceuticals, Inc.
    Study sites
    Baylor College of Medicine · DM Clinical
    Registry record
    NCT07226661 · updated
  2. A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 85
    • All sexes
    Sponsor
    Cybin IRL Limited
    Study site
    Brain Health Consultants and TMS Center
    Registry record
    NCT06793397 · updated
  3. Regulated Stimulation for Optimized Network Activity and Therapeutic Equilibrium

    • No phase
    • Ages 22 to 85
    • All sexes
    Sponsor
    Motif Neurotech, Inc.
    Study sites
    Brain Health Consultants and TMS Center · UTHealth Houston
    Registry record
    NCT07594483 · updated
  4. ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response

    • Phase 2
    • Ages 18 to 65
    • All sexes
    Sponsor
    ACADIA Pharmaceuticals Inc.
    Study site
    Baylor College of Medicine
    Registry record
    NCT07284667 · updated
  5. A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression

    • No phase
    • Ages 18 and older
    • All sexes
    Sponsor
    LivaNova
    Study site
    The University Of Texas Medical School At Houston - UT Center Of Excellence On Mood Disorders
    Registry record
    NCT03887715 · updated
  6. Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Intra-Cellular Therapies, Inc.
    Study site
    DM Clinical Research
    Registry record
    NCT05850689 · updated
  7. Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy

    • Phase 2
    • Ages 25 and older
    • All sexes
    Sponsor
    M.D. Anderson Cancer Center
    Study site
    MD Anderson Cancer Center
    Registry record
    NCT06200155 · updated
  8. Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients

    • Phase 3
    • Ages 10 to 17
    • All sexes
    Sponsor
    Intra-Cellular Therapies, Inc.
    Study site
    Kaleidoscope Clinical Research
    Registry record
    NCT06372964 · updated
  9. Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

    • Phase 3
    • Ages 18 to 74
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    Baylor College of Medicine
    Registry record
    NCT06559306 · updated
  10. TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    M.D. Anderson Cancer Center
    Study site
    The University of Texas M. D. Anderson Cancer Center
    Registry record
    NCT06801041 · updated

Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Houston, TX on ClinicalTrials.gov.

Schizophrenia studies recruiting in Houston

  1. A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)

    • Phase 3
    • Ages 13 to 17
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    Memorial Hermann
    Registry record
    NCT07288567 · updated
  2. A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents

    • Phase 3
    • Ages 5 to 17
    • All sexes
    Sponsor
    Karuna Therapeutics, Inc., a Bristol Myers Squibb company
    Study site
    Evolution Research Group
    Registry record
    NCT07424404 · updated
  3. Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

    • Phase 3
    • Ages 5 to 17
    • All sexes
    Sponsor
    Intra-Cellular Therapies, Inc.
    Study sites
    Kaleidoscope Clinical Research · Red Oak Psychiatry Associates
    Registry record
    NCT06229210 · updated

Source: ClinicalTrials.gov. Data processed . See every schizophrenia study recruiting in Houston, TX on ClinicalTrials.gov.

Bipolar disorder studies recruiting in Houston

  1. Novel Bipolar Radiofrequency Ablation Knife in Esophageal Lesions

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    Baylor College of Medicine
    Study site
    Baylor College of Medicine
    Registry record
    NCT06476678 · updated
  2. A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    Elevate Clinical Research-Houston
    Registry record
    NCT07140913 · updated

Source: ClinicalTrials.gov. Data processed . See every bipolar disorder study recruiting in Houston, TX on ClinicalTrials.gov.

ADHD studies recruiting in Houston

  1. The Myelin Disorders Biorepository Project

    • Observational
    • All ages
    • All sexes
    Sponsor
    Children's Hospital of Philadelphia
    Study sites
    Baylor College of Medicine (Texas Children's Hospital) · UT Health Houston
    Registry record
    NCT03047369 · updated
  2. A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Otsuka Pharmaceutical Development & Commercialization, Inc.
    Study site
    Kaleidoscope Clinical Research
    Registry record
    NCT07759154 · updated

Source: ClinicalTrials.gov. Data processed . See every ADHD study recruiting in Houston, TX on ClinicalTrials.gov.

Parkinson's disease studies recruiting in Houston

  1. DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

    • Phase 3
    • Ages 18 and older
    • Female participants
    Sponsor
    AstraZeneca
    Registry record
    NCT06989112 · updated
  2. Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    University of Texas MD Anderson Cancer Center ( Site 6920)
    Registry record
    NCT06469944 · updated
  3. Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    Boston Scientific Corporation
    Study site
    Houston Methodist Research Institute
    Registry record
    NCT02071134 · updated
  4. A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Oncology Consultants P.A. ( Site 0113)
    Registry record
    NCT06345729 · updated
  5. A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study sites
    Kelsey-Seybold Clinic ( Site 0040) · Kelsey-Seybold Clinic - North Houston Campus ( Site 0096)
    Registry record
    NCT06841354 · updated
  6. A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

    • Phase 3
    • Ages 18 and older
    • Female participants
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Houston Methodist Hospital ( Site 6057)
    Registry record
    NCT06952504 · updated
  7. A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study sites
    Kelsey-Seybold Clinic ( Site 0042) · Kelsey-Seybold Clinic ( Site 0088) · Oncology Consultants P.A. ( Site 0073)
    Registry record
    NCT06966700 · updated
  8. Analysis of Cutaneous Phosphorylated Alpha-Synuclein to Identify Patients at Risk of Progressing From Essential Tremor to Parkinson's Disease

    • Observational
    • Ages 50 to 85
    • All sexes
    Sponsor
    CND Life Sciences
    Study site
    Baylor College of Medicine
    Registry record
    NCT07428447 · updated
  9. A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study sites
    Houston Methodist Cancer Center ( Site 0191) · MD Anderson Cancer Center ( Site 0150) · Memorial Hermann Cancer Center ( Site 0172)
    Registry record
    NCT06623422 · updated
  10. A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

    • Phase 3
    • Ages 18 and older
    • Female participants
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Houston Methodist Hospital-Obstetrics and Gynecology ( Site 6010)
    Registry record
    NCT07216703 · updated

Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Houston, TX on ClinicalTrials.gov.

Multiple sclerosis (MS) studies recruiting in Houston

  1. Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    UT MD Anderson Cancer Center
    Registry record
    NCT03816345 · updated

Source: ClinicalTrials.gov. Data processed . See every multiple sclerosis study recruiting in Houston, TX on ClinicalTrials.gov.

Epilepsy studies recruiting in Houston

  1. Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Rapport Therapeutics Inc.
    Registry record
    NCT07594119 · updated

Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in Houston, TX on ClinicalTrials.gov.

Migraine studies recruiting in Houston

  1. Study of EVO756 in Adults With Migraine

    • Phase 2
    • Ages 18 to 64
    • All sexes
    Sponsor
    Evommune, Inc.
    Study sites
    Mercury Clinical Research Inc. - Houston Neurology Associates · SFF Medical Research Group LLC
    Registry record
    NCT07616128 · updated

Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in Houston, TX on ClinicalTrials.gov.

Ask about studies near Houston

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Texas

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

CNS Clinical Research does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 520-7418

or send a short form

How should we reach you?

Call